NEW YORK (Reuters) – U.S. stocks closed little changed on Friday, but Wall Street wrapped up its best month in a year after the earnings season rounded the final turn with a group of strong results that offset the impact of poor economic data.
NEW YORK (Reuters) – U.S. stocks are unlikely to break above a key technical level next week unless monthly jobs data and consumer company results paint a more promising picture of the recovery.
NEW YORK (Reuters) – New York Attorney General Andrew Cuomo has subpoenaed six more insurers as the state widens a probe into whether life insurance companies have defrauded families of deceased members of the military.
NEW YORK (Reuters) – U.S. stocks closed little changed on Friday, but Wall Street wrapped up its best month in a year after the earnings season rounded the final turn with a group of strong results that offset the impact of poor economic data.
NEW YORK (Reuters) – Stocks fell on Friday, rebounding for a second day in a row from more substantial losses, as concerns about slower economic growth held trading to a tight range.
NEW YORK (Reuters) – Stocks eased slightly on Friday, but for the second day in a row major indexes bounced off session lows, this time on a positive report on Midwest manufacturing activity.
NEW YORK (Reuters) – Stocks reversed course on Friday with the major indexes turning positive after a barometer of U.S. Midwest business jumped in July, while consumer sentiment data for the month came in better than expected.
NEW YORK/SAN FRANCISCO (Reuters) – Chevron Corp, the second-largest U.S. oil company, reported a three-fold jump in quarterly profit, beating expectations as refinery margins fattened.
NEW YORK (Reuters) – Consumer sentiment plunged in July to its lowest level in 9 months on bleak prospects for jobs and income a year since the economic recovery began, a private survey released on Friday showed.
NEW YORK (Reuters) – Merck and Co issued a more cautious 2010 profit outlook on Friday and reported disappointing second-quarter sales of its vaccines and Singulair asthma drug, sending its shares down more than 3 percent.
